0
Article |

Clinical Trials of RA 27/3 (Wistar) Rubella Vaccine in Japan FREE

Toru Furukawa, MD; Takao Miyata, MD; Keizo Kondo, MD; Kuniyoshi Kuno, MD; Shin Isomura, MD; Terko Takekoshi, MD
[+] Author Affiliations

Received for publication March 10, 1969.

Read before the International Conference of Rubella Immunization, Bethesda, Md, Feb 19, 1969.

Reprint requests to Nagoya University, School of Medicine, Nagoya, Japan (Dr. Furukawa).


Am J Dis Child. 1969;118(2):262-263. doi:10.1001/archpedi.1969.02100040264021.
Text Size: A A A
Published online

ABSTRACT

THREE trials were conducted in Nagoya, Japan, testing the safety, antigenicity, contagiousness, and transplacental passage of RA27/3.

Trial 1 was performed with children in a closed orphanage and with nurses attached to two hospitals in Nagoya. Most of the 43 seronegative subjects in the orphanage were between 1 and 2 years of age, with a range from 8 to 35 months. The other subjects were 16 adult women whose ages ranged from 19 to 25 years. In the orphanage, seven rubella susceptible uninoculated children were placed in two rooms where there was ample opportunity for close contact with inoculated children, while playing and napping together.

In the other two trials, the subjects were selected from nursing students at another hospital; 105 were seropositive, and 21 were seronegative. The total number inoculated in the three trials, therefore, included 80 seronegative and 111 seropositive subjects. Of the seronegative subjects, 37 were

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.